Abstract
Nowadays, as a standard of care treatment of several cancers, immune checkpoint inhibitors have changed the field of oncology. However, their empowerment of T cell-mediated anti-tumor immunity bears the risk for injury of various organs as a side effect. Many years of treatment with immune checkpoint inhibitors have taught oncologists the management of common immune-related adverse events such as cutaneous, gastrointestinal, lung and cardiovascular toxicities. Nonetheless, there is still a lack of knowledge about different mechanisms, significance and management of pancreatic involvement during immune checkpoint inhibition. In this review, we examine the current evidence on lipase elevation, acute pancreatitis, diabetes mellitus and pancreatic exocrine insufficiency related to immune checkpoint inhibition. We further present approaches of diagnosis and management of these adverse events.
Keywords
Immune checkpoint inhibition, Lipase, Pancreatitis, Diabetes mellitus, Pancreatic exocrine insufficiency